Skip to content

Our
Science

Antibody-Drug Conjugates (ADCs)

Antibody-drug conjugates (ADCs) are a highly-targeted type of cancer treatment designed to specifically deliver chemotherapies directly to tumor cells—all while sparing healthy cells. The key to this type of therapy is getting three distinct molecules to work together.

The 3 Key Molecular Players in ADCs
01-antibody-icon
Antibody (monoclonal)
Binds to a protein or antigen expressed on tumor cells
02-active-drug-icon
Active drug (chemotherapy)
Designed to kill a tumor cell once inside
03-linker-icon
Linker
Stable molecular link between the antibody and active drug

The ADC travels throughout the body until the monoclonal antibody recognizes a tumor cell expressing the targeted antigen. The ADC binds to the cell and is brought inside, where the linker releases the chemotherapy payload, leading to the death of the tumor cell. ADCs, while a proven therapeutic, currently have limited scope—but RemeGen’s therapeutics will expand the class to include the most serious diseases in oncology and beyond.

Publications
RC28
Bifunctional Antibody Platform
Two are better than one—these dual-acting antibodies can target multiple regulating molecules at once to slow disease progression.
More about bifunctional antibodies
RC18
Antibody and Fusion Protein R&D Platform
By taking the best pieces of different proteins to create new fusion antibodies, we can better target the immune system in autoimmune diseases.
More about antibody and fusion proteins